Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,414,660
  • Shares Outstanding, K 284,908
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,578 M
  • EBITDA $ 5,040 M
  • 60-Month Beta 0.23
  • Price/Sales 2.64
  • Price/Cash Flow 8.78
  • Price/Book 2.29

Options Overview Details

View History
  • Implied Volatility 30.42% (-0.84%)
  • Historical Volatility 23.50%
  • IV Percentile 76%
  • IV Rank 57.46%
  • IV High 40.49% on 04/10/25
  • IV Low 16.81% on 02/11/25
  • Expected Move (DTE 2) 3.91 (1.89%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,178
  • Volume Avg (30-Day) 614
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 26,792
  • Open Int (30-Day) 27,278
  • Expected Range 203.51 to 211.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.82
  • Number of Estimates 7
  • High Estimate 2.85
  • Low Estimate 2.79
  • Prior Year 3.43
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.48 +7.76%
on 01/02/26
207.64 -0.11%
on 01/14/26
+6.53 (+3.25%)
since 12/12/25
3-Month
162.29 +27.81%
on 11/06/25
207.64 -0.11%
on 01/14/26
+19.06 (+10.12%)
since 10/14/25
52-Week
162.29 +27.81%
on 11/06/25
251.99 -17.69%
on 02/03/25
-28.38 (-12.04%)
since 01/14/25

Most Recent Stories

More News
BD Names Shawn Bevec as Senior Vice President of Investor Relations

FRANKLIN LAKES, N.J. , Jan. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shawn Bevec has been named...

BDX : 207.42 (+2.93%)
BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

Introduces BD Neopakâ„¢ Glass Prefillable Syringe production in Columbus, Nebraska

BDX : 207.42 (+2.93%)
BD To Host Virtual 2026 Annual Meeting of Shareholders

FRANKLIN LAKES, N.J. , Jan. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2026...

BDX : 207.42 (+2.93%)
3 Undervalued Dividend Kings Built for Reliable Income in 2026

Income focused investors can find value today in long standing dividend growers trading at reasonable prices, backed by durable businesses and steady cash flow.

BDX : 207.42 (+2.93%)
FRT : 102.02 (-0.07%)
NUE : 172.29 (+1.66%)
1 S&P 500 Stock to Own for Decades and 2 We Ignore

1 S&P 500 Stock to Own for Decades and 2 We Ignore

RTX : 198.84 (+2.45%)
BDX : 207.42 (+2.93%)
CTAS : 194.23 (+0.78%)
What to Expect From Becton, Dickinson and Company's Next Quarterly Earnings Report

Becton, Dickinson and Company is ready to unveil its fiscal first-quarter earnings soon, and analysts project a double-digit profit drop.

XLV : 157.86 (+0.71%)
$SPX : 6,926.60 (-0.53%)
BDX : 207.42 (+2.93%)
Waters Corporation Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT

NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

BDX : 207.42 (+2.93%)
WAT : 393.20 (-0.21%)
BD Marks Milestone with First Phasixâ„¢ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

FRANKLIN LAKES, N.J. , Jan. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced...

BDX : 207.42 (+2.93%)
BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscoverâ„¢ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

BDX : 207.42 (+2.93%)
Is Solventum Stock Outperforming the Nasdaq?

Solventum has delivered stronger performance than the Nasdaq Composite over the past year, reinforcing analysts’ moderate optimism regarding the stock’s forward outlook.

SOLV : 80.05 (+0.02%)
$NASX : 23,471.75 (-1.00%)
BDX : 207.42 (+2.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 216.60
2nd Resistance Point 212.12
1st Resistance Point 209.77
Last Price 207.42
1st Support Level 202.94
2nd Support Level 198.46
3rd Support Level 196.11

See More

52-Week High 251.99
Fibonacci 61.8% 217.72
Last Price 207.42
Fibonacci 50% 207.14
Fibonacci 38.2% 196.55
52-Week Low 162.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar